Challenges in development of orally disintegrating and dispersible

Challenges in development of orally disintegrating and dispersible tablets. By V.SRUJANA M.Pharm ( 1 st SEM ) DEPARTMENT OF PHARMACEUTICS

CONTENTS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

INTRODUCTION ,[object Object],[object Object],[object Object],[object Object],[object Object]

Terminologies for ODTs ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Advantages over the conventional dosage form ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Challenges in the product design, formulation and manufacture of ODTs. ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

PALATABILITY ,[object Object],[object Object],[object Object],[object Object],[object Object]

General taste masking technologies in oral solid dosage forms: ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Detection threshold of sensors compared to Human receptors ,[object Object],[object Object],[object Object],Electronic tongue Human tongue Taste basic substance Taste 5x10 -6 1x10 -6 2x10 -6 9x10 -4 0.7x10 -3 1x10 -2 HCl Sourness Caffeine Bitterness Sucrose Sweetness

The active moiety in pharmaceutical product cannot be therapeutically beneficial unless it has preference and acceptance by the patient. Thus, pleasant taste is important for the therapeutic success of the drug formulation. ,[object Object],[object Object]

Objectives of electronic tongue: ,[object Object],[object Object],[object Object],[object Object]

MECHANICAL STRENGTH ,[object Object],[object Object],[object Object],[object Object],[object Object]

AMOUNT OF DRUG ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

SIZE OF TABLET ,[object Object],[object Object],[object Object],[object Object],[object Object]

HYGROSCOPICITY ,[object Object],[object Object],[object Object],[object Object]

AQUEOUS SOLUBILITY ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

SHORT HALF-LIFE ,[object Object],[object Object],[object Object],[object Object],[object Object]

COST OF THE TABLET ,[object Object],[object Object]

Materials required: ,[object Object],[object Object]

THE IDEAL CHARACTERISTICS OF DRUG ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

EXCIPIENTS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

OTHER EXCIPIENTS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

MECHANISMS OF DRUG RELEASE ,[object Object]

MECHANISM OF SUPERDISINTEGRANTS ,[object Object],[object Object],[object Object],[object Object]

DEFORMATION AND REPULSION ,[object Object]

WICKING AND SWELLING ,[object Object]

FORMULATION TECHNIQUES ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Tablet Molding ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

DIRECT COMPRESSION ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

SPRAY DRYING ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

FREEZE DRYING OR LYOPHILIZATION ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

MASS EXTRUSION ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

COTTON CANDY PROCESS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

PATENTED TECHNOLOGIES ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

ZYDIS TECHNOLOGY ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

ORASOLV TECHNOLOGY ,[object Object],[object Object],[object Object],[object Object]

DURASOLV TECHNOLOGY ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

WOWTAB TECHNOLOGY ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

FLASH DOSE TECHNOLOGY ,[object Object],[object Object],[object Object],[object Object],[object Object]

FLASH TAB TECHNOLOGY ,[object Object],[object Object],[object Object],[object Object],[object Object]

DRUGS INCORPORATED IN ODTs ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

PREFORMULATION STUDIES ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Some of the Marketed ODTs in India Famotidine (20-40 mg) Pepcid RPD Micronized Loratadine Claritin Reditab Nimesulide Nimulid -MD Olanzapine (5, 10, 15 or 20 mg) Zyprexa Zydis Piroxicam(10-20 mg) Feldene Melt Active Ingredient Name of product

EVALUATION TESTS ,[object Object],[object Object],[object Object]

FRIABILITY TEST ,[object Object],[object Object],[object Object]

WETTING TIME AND WATER ABSORPTION RATIO ,[object Object],[object Object],[object Object]

HARDNESS TEST ,[object Object],[object Object]

MOISTURE UPTAKE TEST ,[object Object],[object Object],[object Object]

MEASUREMENT OF TABLET POROSITY ,[object Object],[object Object],[object Object]

IN-VITRO DISPERSION TIME ,[object Object],[object Object]

IN-VITRO DISINTEGRATION TEST ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

DISINTEGRATION APPARATUS ,[object Object]

DISINTEGRATION USING TEXTURE ANALYZER ,[object Object]

IN-VITRO DISSOLUTION STUDY ,[object Object],[object Object],[object Object],[object Object]

FUTURE DEVELOPMENTS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

CONCLUSION ,[object Object],[object Object],[object Object]

REFERENCES ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Challenges in development of orally disintegrating and dispersible

Recommandé

Recommandé

Contenu connexe

Tendances

Tendances (20)

En vedette

En vedette (20)

Similaire à Challenges in development of orally disintegrating and dispersible

Similaire à Challenges in development of orally disintegrating and dispersible (20)

Dernier

Dernier (20)

Challenges in development of orally disintegrating and dispersible